News

Pharmamar’s new  candidate avails
Enlarge image

OncologySpain

Pharmamar’s new candidate avails

03.10.2012 - Clinical data presented at a Congress in Vienna shows that a new Pharmamar drug could step up to the success of its paragon Yondelis.

Pharmamar S.A. from Colmenar Viejo is part of Spain’s largest biotech Zeltia S.A. It is known for its marine tunicate-derived anti-cancer drug Yondelis. But there is another potentially marketable drug named PM01183 (lurbinectedin) in the pipeline. On 30 September, new clinical data was presented at the 37th Congress of the European Society of Molecular Oncology (ESMO) in Vienna. Results from the first part of a two-stage Phase II study in patients with platinum-resistant or refractory ovarian cancers were well-perceived, where a confirmed response to the treatment was observed in 6 out of 22 patients. Moreover, the disease had only progressed in 6 patients at the first evaluation, which means that the tumour remained stable in the remaining 10 patients (disease control rate: 73%). The drug showed no toxicity-related problems. The second stage was launched in April with the enrolment of 60 additional patients, who will be randomised to either the PM01183 arm or the active comparator arm where GSK’s topotecan is given.

Other indications where PM01183’s potential is scrutinised include non-small-cell lung carcinoma and breast cancer. Data of a Phase Ib study also presented at the meeting suggest that a combination of PM01183 with the nucleoside analogue gemcitabine improves the anti-tumour activities in the first mentioned indication when compared to treatments with each drug alone. The latter indication is dealt with in a Phase II study with metastatic breast cancer (MBC) patients which started in June this year. Here, patients are stratified into one group where the women have certain deleterious germline mutations in BRCA1/2 and another with woman without such mutations. Pharmamar wants to show that PM01183 works for BRCA 1/2-associated MBCs.

Pharmamar also tries to widen the scope of Yondelis, the first cancer medication ever to be developed in Spain. Moving from 2nd line to 1st line indications Yondelis (trabectedin) is currently under investigation for its strength to fight non-operable and/or metastatic soft tissue sarcomas. In the trial named GEIS-20 standard doxorubicin treatment is compared against a doxorubicin-trabectedin-combination. Results of the Phase II, open label, randomised study with 182 patients are expected in Q4/12.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/pharmamars-new-candidate-avails.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • FORMYCON24.58 EUR6.18%
  • CYTOS1.45 CHF3.57%

FLOP

  • MEDIGENE10.52 EUR-9.70%
  • BIOFRONTERA2.53 EUR-3.44%
  • 4SC1.25 EUR-2.34%

TOP

  • CYTOS1.45 CHF326.5%
  • MEDIGENE10.52 EUR147.5%
  • 4SC1.25 EUR60.3%

FLOP

  • MORPHOSYS56.55 EUR-24.4%
  • WILEX3.00 EUR-12.5%
  • BASILEA108.00 CHF-11.6%

TOP

  • SANTHERA92.40 CHF2269.2%
  • WILEX3.00 EUR400.0%
  • FORMYCON24.58 EUR251.1%

FLOP

  • CYTOS1.45 CHF-51.3%
  • MOLOGEN5.81 EUR-48.7%
  • PAION2.34 EUR-29.9%

No liability assumed, Date: 29.03.2015